|
1
|
Lu J, Steeg PS, Price JE, et al: Breast
cancer metastasis: challenges and opportunities. Cancer Res.
69:4951–4953. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Muller A, Homey B, Soto H, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mukherjee D and Zhao J: The role of
chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer
Res. 3:46–57. 2013.PubMed/NCBI
|
|
4
|
Gil M, Seshadri M, Komorowski MP, Abrams
SI and Kozbor D: Targeting CXCL12/CXCR4 signaling with oncolytic
virotherapy disrupts tumor vasculature and inhibits breast cancer
metastases. Proc Natl Acad Sci USA. 110:E1291–E1300. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luker KE and Luker GD: Functions of CXCL12
and CXCR4 in breast cancer. Cancer Lett. 238:30–41. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fernandis AZ, Prasad A, Band H, Klosel R
and Ganju RK: Regulation of CXCR4-mediated chemotaxis and
chemoinvasion of breast cancer cells. Oncogene. 23:157–167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rhodes LV, Short SP, Neel NF, et al:
Cytokine receptor CXCR4 mediates estrogen-independent
tumorigenesis, metastasis, and resistance to endocrine therapy in
human breast cancer. Cancer Res. 71:603–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prasad A, Fernandis AZ, Rao Y and Ganju
RK: Slit protein- mediated inhibition of CXCR4-induced chemotactic
and chemoinvasive signaling pathways in breast cancer cells. J Biol
Chem. 279:9115–9124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang Z, Brooks J, Willard M, et al:
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through
Akt signaling pathway. Biochem Biophys Res Commun. 359:716–722.
2007. View Article : Google Scholar
|
|
10
|
Vila-Coro AJ, Rodriguez-Frade JM, Martin
De Ana A, Moreno-Ortiz MC, Martinez AC and Mellado M: The chemokine
SDF-1alpha triggers CXCR4 receptor dimerization and activates the
JAK/STAT pathway. FASEB J. 13:1699–1710. 1999.PubMed/NCBI
|
|
11
|
Ahr B, Denizot M, Robert-Hebmann V, Brelot
A and Biard-Piechaczyk M: Identification of the cytoplasmic domains
of CXCR4 involved in Jak2 and STAT3 phosphorylation. J Biol Chem.
280:6692–6700. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ling X, Konopleva M, Zeng Z, et al: The
novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1,
9-dien-28-oic acid inhibits metastatic murine breast tumor growth
through inactivation of STAT3 signaling. Cancer Res. 67:4210–4218.
2007. View Article : Google Scholar
|
|
13
|
Alvarez JV, Febbo PG, Ramaswamy S, Loda M,
Richardson A and Frank DA: Identification of a genetic signature of
activated signal transducer and activator of transcription 3 in
human tumors. Cancer Res. 65:5054–5062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Germain D and Frank DA: Targeting the
cytoplasmic and nuclear functions of signal transducers and
activators of transcription 3 for cancer therapy. Clin Cancer Res.
13:5665–5669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al Zaid Siddiquee K and Turkson J: STAT3
as a target for inducing apoptosis in solid and hematological
tumors. Cell Res. 18:254–267. 2008.PubMed/NCBI
|
|
16
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
et al: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar
|
|
17
|
Turkson J: STAT proteins as novel targets
for cancer drug discovery. Expert Opin Ther Targets. 8:409–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Crowe PJ, Goldstein D and Yang JL:
STAT3 inhibition, a novel approach to enhancing targeted therapy in
human cancers (Review). Int J Oncol. 14:1181–1191. 2012.PubMed/NCBI
|
|
19
|
Groner B, Lucks P and Borghouts C: The
function of Stat3 in tumor cells and their microenvironment. Semin
Cell Dev Biol. 19:341–350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Soriano SF, Serrano A, Hernanz-Falcon P,
et al: Chemokines integrate JAK/STAT and G-protein pathways during
chemotaxis and calcium flux responses. Eur J Immunol. 33:1328–1333.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moriguchi M, Hissong BD, Gadina M, et al:
CXCL12 signaling is independent of Jak2 and Jak3. J Biol Chem.
280:17408–17414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Majka M, Drukala J, Lesko E, Wysoczynski
M, Jenson AB and Ratajczak MZ: SDF-1 alone and in co-operation with
HGF regulates biology of human cervical carcinoma cells. Folia
Histochem Cytobiol. 44:155–164. 2006.PubMed/NCBI
|
|
23
|
Pfeiffer M, Hartmann TN, Leick M, Catusse
J, Schmitt-Graeff A and Burger M: Alternative implication of CXCR4
in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer.
100:1949–1956. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen B, Zheng MQ, Lu JW, Jiang Q, Wang TH
and Huang XE: CXCL12-CXCR4 promotes proliferation and invasion of
pancreatic cancer cells. Asian Pac J Cancer Prev. 14:5403–5408.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee HJ, Kim SW, Kim HY, et al: Chemokine
receptor CXCR4 expression, function, and clinical implications in
gastric cancer. Int J Oncol. 34:473–480. 2009.PubMed/NCBI
|
|
26
|
Diaz N, Minton S, Cox C, et al: Activation
of stat3 in primary tumors from high-risk breast cancer patients is
associated with elevated levels of activated SRC and survivin
expression. Clin Cancer Res. 12:20–28. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ling X and Arlinghaus RB: Knockdown of
STAT3 expression by RNA interference inhibits the induction of
breast tumors in immunocompetent mice. Cancer Res. 65:2532–2536.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Selander KS, Li L, Watson L, et al:
Inhibition of gp130 signaling in breast cancer blocks constitutive
activation of Stat3 and inhibits in vivo malignancy. Cancer Res.
64:6924–6933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao L, Wang L, Jin F, et al: Silencing of
estrogen receptor alpha (ERalpha) gene by promoter hypermethylation
is a frequent event in Chinese women with sporadic breast cancer.
Breast Cancer Res Treat. 117:253–259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bai X, Jin F, Fu Y, et al:
Clinicopathological significance and prognostic value of Xeroderma
pigmentosum complementary group C (XPC) expression in sporadic
breast cancer patients. Med Oncol. 29:1543–1553. 2012. View Article : Google Scholar
|
|
31
|
Pellegrini S and Dusanter-Fourt I: The
structure, regulation and function of the Janus kinases (JAKs) and
the signal transducers and activators of transcription (STATs). Eur
J Biochem. 248:615–633. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu TP, Shen H, Liu LX and Shu YQ: The
impact of chemokine receptor CXCR4 on breast cancer prognosis: A
meta-analysis. Cancer Epidemiol. 37:725–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin F, Brockmeier U, Otterbach F and
Metzen E: New insight into the SDF-1/CXCR4 axis in a breast
carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell
CXCR4 are required for tumor cell intravasation. Mol Cancer Res.
10:1021–1031. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang M, Liu HX, Teng XD, et al: The
differences in CXCR4 protein expression are significant for the
five molecular subtypes of breast cancer. Ultrastruct Pathol.
36:381–386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ling X, Spaeth E, Chen Y, et al: The CXCR4
antagonist AMD3465 regulates oncogenic signaling and invasiveness
in vitro and prevents breast cancer growth and metastasis in vivo.
PLoS One. 8:e584262013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hao L, Zhang CH, Qiu YH, et al:
Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node
metastasis in human breast cancer. Cancer Lett. 253:34–42. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Andre F, Xia WY, Conforti R, et al: CXCR4
expression in early breast cancer and risk of distant recurrence.
Oncologist. 14:1182–1188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cabioglu N, Yazici MS, Arun BK, et al:
Expression of CXCR4 predicts lymph node metastasis in early breast
cancer. J Clin Oncol. 22:841s. 2004.
|
|
40
|
Schioppa T, Uranchimeg B, Saccani A, et
al: Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp
Med. 198:1391–1402. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li YM, Pan Y, Wei Y, et al: Upregulation
of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer
Cell. 6:459–469. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rahimi M, George J and Tang C: EGFR
variant-mediated invasion by enhanced CXCR4 expression through
transcriptional and post-translational mechanisms. Int J Cancer.
126:1850–1860. 2010.PubMed/NCBI
|
|
43
|
Zhao XP, Huang YY, Huang Y, et al:
Transforming growth factor-beta1 upregulates the expression of CXC
chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells.
Acta Pharmacol Sin. 31:347–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dechow TN, Pedranzini L, Leitch A, et al:
Requirement of matrix metalloproteinase-9 for the transformation of
human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA.
101:10602–10607. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Berishaj M, Gao SP, Ahmed S, et al: Stat3
is tyrosine-phosphorylated through the interleukin-6/glycoprotein
130/Janus kinase pathway in breast cancer. Breast Cancer Res.
9:R322007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marotta LL, Almendro V, Marusyk A, et al:
The JAK2/STAT3 signaling pathway is required for growth of
CD44+CD24− stem cell-like breast cancer cells
in human tumors. J Clin Invest. 121:2723–2735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Behera R, Kumar V, Lohite K, Karnik S and
Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin
promotes tumor growth in human breast cancer cells. Carcinogenesis.
31:192–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
